Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease (RIVA-KG)

Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease: a Multicenter, Open-label, Parallel, Exploratory, Randomized Controlled Trial

Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed. This exploratory trial aims to evaluate the feasibility, safety and effectiveness of rivaroxaban compared to warfarin for thromboprophylaxis in children aged over 2 years with giant coronary artery aneurysms after Kawasaki disease

Study Overview

• Status: Recruiting
• Conditions: Kawasaki Disease; Coronary Artery Aneurysm
• Intervention / Treatment: Drug: Warfarin; Drug: Rivaroxaban Oral Tablet [Xarelto]; Drug: Aspirin or Clopidogrel

Detailed Description

Lifelong anticoagulant treatment is required in children with giant coronary artery aneurysm after Kawasaki disease, imposing social and psychologic burdens on patients and parents. Rivaroxaban is a potential oral anticoagulant in this population. Considering the impact of ethnic difference and growth development, we proposed a Chinese-specific, optimized dosing regimen based on model- and clinical evidence-informed precision dosing. In the previous pilot study, this optimized dosing regimen demonstrated a favorable feasibility among 11 Chinese pediatric patients aged over 2 years with giant coronary artery aneurysm after Kawasaki disease, with no thrombosis or major bleeding over 6 months.

This study is a multicenter, open-label, exploratory, randomized controlled trial to evaluate the feasibility, safety and effectiveness of rivaroxaban for thromboprophylaxis in children aged over 2 years with giant coronary artery aneurysms after Kawasaki disease, following the 15 mg-equivalent dosing regimen. Participants will be randomly assigned to the control or experimental groups. Randomization ratio will be 2:1. The control group will receive warfarin plus aspirin or clopidogrel, and the experimental group will receive rivaroxaban plus aspirin or clopidogrel. Baseline characteristics, treatment effect outcomes, bleeding events, adverse events and compliance of intervention of each participant will be collected.

Because this is an exploratory study and the low incidence of giant coronary artery aneurysm in children with Kawasaki disease, the study plans to recruit 100 participants. The aims include:

• The feasibility
• The safety and efficacy profile of the optimized, 15 mg-equivalent dosing regimen
• The group differences in safety and treatment effect between warfarin and rivaroxaban

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Fang Liu, MD; Phone Number: 18017590880; Email: liufang@fudan.edu.cn
• Study Contact Backup: Name: Guangan Dai; Phone Number: 13580762996; Email: gadai24@m.fudan.edu.cn

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 201102
      • Recruiting
      • Children's Hospital of Fudan University
      • Contact: Fang Liu, MD.
      • Principal Investigator: Fang Liu, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≥10 or coronary artery internal diameter ≥8mm;
2. Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 3 months;
3. Participant should be able to tolerate oral feeding, nasogastric or gastric feeding;
4. Children aged ≥ 2 years

Exclusion Criteria:

1. Active bleeding or bleeding risk contraindicating anticoagulant therapy
2. With history of venous thromboembolism or risk factors related with venous thromboembolism, like congenital heart disease, carcinoma, central venous catheter or long-term immobilization.
3. Thrombus within giant coronary aneurysm was confirmed by previous imaging examinations, including two-dimensional echocardiography, computed tomography angiography in coronary artery or coronary angiography
4. An eGFR <30mL/min/1.73 m2 (For children younger than 1 year, serum creatinine results above 97.5th percentile)
5. Platelet count < 100 x 109/L
6. Hepatic disease which is associated with either: coagulopathy leading to a clinically relevant bleeding risk, or alanine aminotransferase > 5x ULN or total bilirubin > 2x ULN with direct bilirubin > 20% of the total
7. Sustained uncontrolled hypertension defined as systolic and/or diastolic blood pressure >95 th age percentile
8. Concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein, including but not limited to all human immunodeficiency virus protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically (fluconazole is allowed)
9. Concomitant use of strong inducers of CYP3A4, including but not limited to rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
10. Hypersensitivity or any other contraindications listed in the local labeling for the comparator treatment or experimental treatment
11. Inability to cooperate with the study procedures and follow-up visits
12. Refuse to provide informed consent eGFR, estimated glomerular filtration rate; ULN, upper level of normal; TB, total bilirubin; CYP3A4, cytochrome P450 isoenzyme 3A4

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rivaroxaban+Antiplatelet drug; Rivaroxaban as anticoagulant will be administered with antiplatelet drug for 3 months. Antiplatelet drug can choose Aspirin or Clopidogrel depending on participant medical history and physician's recommendation.	Drug: Rivaroxaban Oral Tablet [Xarelto]; Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing; Other Names: Xarelto; Drug: Aspirin or Clopidogrel; Aspirin [3 ~5mg/(kg·d) once daily] or Clopidogrel [1.0 mg/kg; once daily]; Other Names: Antiplatelet therapy
Active Comparator: Standard antithrombotic care; Warfarin as anticoagulant will be administered with antiplatelet drug for 3 months. Antiplatelet drug can choose Aspirin or Clopidogrel depending on participant medical history and physician's recommendation. International normalized ratio(INR) should be tested once a month and maintained in target range(1.5~2.5). 2.Aspirin[3 ~5mg/(kg·d), once daily] or Clopidogrel[ 1.0 mg/kg; once daily] according to experienced clinician recommendation and individual condition.	Drug: Warfarin; Warfarin 0.05~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5; Other Names: Vitamin K Antagonist; Drug: Aspirin or Clopidogrel; Aspirin [3 ~5mg/(kg·d) once daily] or Clopidogrel [1.0 mg/kg; once daily]; Other Names: Antiplatelet therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite of new thrombosis in coronary arteries, major bleeding, clinically relevant non-major bleeding event or major adverse cardiovascular event	It is a binary variable. This composite outcome indicates whether any of the following events occurred within 3 months after treatment initiation: (a) newly developed coronary artery thrombosis; (b) major bleeding event; (c) clinically relevant non-major bleeding event; or (d) major adverse cardiovascular event (defined as unstable angina, acute myocardial infarction, hospitalization for heart failure, unplanned coronary revascularization, stroke, or cardiovascular death).	From Day 1 of treatment to the third month after treatment initiation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of new thrombosis in coronary arteries	It is binary data. Every echocardiography conducted during study period will be assessed by masked sonographer. The masked sonographers will assess whether new thrombosis occurs in coronary arteries, and recorded the number of involved coronary arteries.	From Day 1 of treatment to the third month after treatment initiation
Time to first new thrombosis in coronary arteries	It is time to event data. Every echocardiography conducted during study period will be assessed by masked sonographer. The masked sonographers will assess whether new thrombosis occurs in coronary arteries, and recorded the time to first new thrombosis in coronary arteries.	From Day 1 of treatment to the third month after treatment initiation
Composite of Major bleeding or Clinically relevant non-major bleeding event	It is a binary variable. Major bleeding is defined as 1.Fatal bleeding; 2.Clinically overt bleeding associated with a decrease in Hgb of ≥20 g/L (2 g/dL) in a 24-h period; 3.Critical site bleeding, such as retroperitoneal, pulmonary, pericardial, intracranial, or otherwise involves the central nervous system; 4.Bleeding that requires an intervention via an invasive procedure; 5.Overt bleeding for which a reversal agent is administered. Clinically relevant non-major bleeding event is defined as 1.Bleeding that results in a medical or procedural intervention not meeting major bleeding criteria, including a medication change (reducing, holding, or changing anticoagulation or addition of new medication) ; 2.Bleeding that results in hospitalization or increased level of care; 3.Overt bleeding for which a blood product is administered, and does not meet the criteria for major bleeding	From Day 1 of treatment to the third month after treatment initiation
Occurrence of major bleeding	It is a binary variable. Major bleeding is defined as 1.Fatal bleeding; 2.Clinically overt bleeding associated with a decrease in Hgb of ≥20 g/L (2 g/dL) in a 24-h period; 3.Critical site bleeding, such as retroperitoneal, pulmonary, pericardial, intracranial, or otherwise involves the central nervous system; 4.Bleeding that requires an intervention via an invasive procedure; 5.Overt bleeding for which a reversal agent is administered.	From Day 1 of treatment to the third month after treatment initiation
Occurrence of clinically relevant non-major bleeding (CRNM)	It is a binary variable. Clinically relevant non-major bleeding event is defined as 1.Bleeding that results in a medical or procedural intervention not meeting major bleeding criteria, including a medication change (reducing, holding, or changing anticoagulation or addition of new medication) ; 2.Bleeding that results in hospitalization or increased level of care; 3.Overt bleeding for which a blood product is administered, and does not meet the criteria for major bleeding	From Day 1 of treatment to the third month after treatment initiation
Occurence of patient important bleeding, no intervention (PIBNI)	It is a binary variable. PIBNI is defined as bleeding for which medical attention is sought (phone call, telehealth, clinic, or emergency department visit) but does not result in hospitalization, increased level of inpatient care, or an intervention by the medical team	From Day 1 of treatment to the third month after treatment initiation
Occurence of minor bleeding	It is a binary variable. Minor bleeding is defined as any overt or macroscopic evidence of bleeding that does not ful ll the above criteria for either fi major bleeding, clinically relevant, non-major bleeding, or patient important bleeding without intervention	From Day 1 of treatment to the third month after treatment initiation
Occurrence of major adverse cardiovascular event	It is binary variable. Major adverse cardiovascular event (MACE) includes unstable angina, acute myocardial infarction, stroke, hospitalization for heart failure, unplanned revascularization, cardiovascular death. If any of the MACEs occur during the study period, it will be recorded as 1; otherwise, it will be recorded as 0. The definition of each MACE refers to the following guidelines and consensus: 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, 2019 European society of Cardiology (ESC) guidelines for the diagnosis and management of chronic coronary syndromes, Fourth universal definition of myocardial infarction, and 2023 ESC Guidelines for the management of acute coronary syndromes.	From Day 1 of treatment to the third month after treatment initiation
Time to major adverse cardiovascular event	It is time to event data. Major adverse cardiovascular event (MACE) includes unstable angina, acute myocardial infarction, stroke, hospitalization for heart failure, unplanned revascularization, cardiovascular death. If any of the MACEs occur during the study period, the time to MACE will be recorded.	From Day 1 of treatment to the third month after treatment initiation
Any adverse events	It is a text variable. If any adverse events( including durg allergy, severe infection, hepatic dysfunction, renal dysfunction, hypertension, fatigue, abdominal pain or others) occur will be reported to the data and safety monitoring board. The detail of adverse event will be recorded, including classification of adverse event, time of occurrence, symptoms, treatment, resolution time, and outcome.	From Day 1 of treatment to the third month after treatment initiation
Plasma concentration of rivaroxaban at specific timepoints	For experimental group, plasma concentration of rivaroxaban concentration will be measured by high performance liquid chromatography tandem mass spectrometer. Based on the principle of sparse sampling, predefined timepoints for measurement include: 1. Day 1, 20 minutes -1 h after the first dose; 2. Day 1, 7±1 h after the first dose; 3. After at least three continuous doses (≥ Day 4): before the scheduled dose at that day, which is defined as the trough concentration; 4. After at least three continuous doses (≥ Day 4): 3±1 h the scheduled dose at that day, which is defined as the peak concentration. 5. Peak concentrations during scheduled follow-up: 45±10 days, and 90±10 days; 6. Trough concentrations during scheduled follow-up: 45±10 days, and 90±10 days;	From Day 1 of treatment to the third month after treatment initiation
Anti-factor Xa activity at specific timepoints	For experimental group, anti-factor Xa activity will be measured by rivaroxaban calibrated chromogenic anti-factor Xa assay. Based on the principle of sparse sampling, predefined timepoints for measurement include: 1. Peak concentrations in scheduled follow-up (45±10 days, and 90±10 days): 3±1 h the scheduled dose at that day; 2. Trough concentrations in scheduled follow-up (45±10 days, and 90±10 days): before the scheduled dose at that day	From Day 1 of treatment to the third month after treatment initiation
Discontinuation anticoagulant due to regression of coronary artery lesions	It is a binary variable. During study period, researchers will assess and recommend to discontinue anticoagulant if coronary artery lesions regress, which will be confirmed by echocardiography, coronary artery computerized tomography angiography, or coronary artery angiography.	From Day 1 of treatment to the third month after treatment initiation
Changes in Z-score of each coronary artery aneurysms	This is a repeated measurement. On day 0, an initial echocardiography will be performed by masked sonographer to assess coronary artery lesions. The maximum internal diameter of coronary artery lesion will be measured and recorded. With data of height, bodyweight and internal diameter, Z-score will be calculated (Journal of the American Society of Echocardiography, 2011, 24(1)). If multiple coronary artery aneurysms exists, internal diameter and Z-score will be measured, calculated and recorded separately. Repeated echocardiographies will be conducted at each scheduled visit (45±10 days、90±10 days).	From Day 1 of treatment to the third month after treatment initiation
Anticoagulation Monitoring-Related Cost	Total healthcare resource utilization cost directly related to anticoagulation monitoring. This includes: Laboratory test costs (e.g., INR testing cost in the control group, calculated as the number of INR tests multiplied by the unit cost per test; anti-Xa activity testing cost in the intervention group, calculated as the number of anti-Xa tests multiplied by the unit cost per test);; Medical service costs (e.g., additional outpatient or emergency visits, medication adjustments, follow-up visits, consultations, and telephone follow-ups due to abnormal INR values).	From Day 1 of treatment to the third months after treatment initiation

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Genetic polymorphism	For experimental group, the rest blood sample from rivaroxaban plasma concentration measurement will be collected for genetic polymorphisms examination. Genes related to rivaroxaban metabolism and transport will be examined, including CYP3A4, ABCB1, ABCG2, and et.cl CYP3A4: Cytochrome P450 Family 3 Subfamily A Member 4, ABCB1: ATP Binding Cassette Subfamily B Member 1; ABCG2: ATP Binding Cassette Subfamily G Member 2	From Day 1 of treatment to the third month after treatment initiation

Collaborators and Investigators

• Sponsor: Children's Hospital of Fudan University
• Investigators: Study Director: Fang Liu, MD, Children's Hospital of Fudan University

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2025
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: November 25, 2022
• First Submitted That Met QC Criteria: December 6, 2022
• First Posted (Actual): December 9, 2022

Study Record Updates

• Last Update Posted (Actual): July 2, 2025
• Last Update Submitted That Met QC Criteria: June 29, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Keywords: Rivaroxaban; Anticoagulation; Warfarin; Kawasaki disease; Giant coronary artery aneurysm
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Heart Diseases; Skin Diseases; Lymphatic Diseases; Skin Diseases, Vascular; Coronary Disease; Myocardial Ischemia; Vasculitis; Aneurysm; Mucocutaneous Lymph Node Syndrome; Coronary Aneurysm; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Peripheral Nervous System Agents; Protease Inhibitors; Enzyme Inhibitors; Antifibrinolytic Agents; Fibrin Modulating Agents; Hemostatics; Coagulants; Antirheumatic Agents; Sensory System Agents; Analgesics, Non-Narcotic; Analgesics; Antipyretics; Neurotransmitter Agents; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Fibrinolytic Agents; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Micronutrients; Vitamins; Anticoagulants; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Clopidogrel; Rivaroxaban; Aspirin; Vitamin K; Warfarin
• Other Study ID Numbers: 2022-399

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No